HF
ABUS icon

HRT Financial’s Arbutus Biopharma ABUS Stock Holding History

HRT Financial’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-50,617
Closed -$150K – 2843
2022
Q1 		$150K Buy
+50,617
New +$155K ﹤0.01% 2558
2021
Q4 		– Sell
-18,724
Closed -$80K – 3079
2021
Q3 		$80K Buy
+18,724
New +$62.4K ﹤0.01% 2959
2021
Q1 		– Sell
-28,054
Closed -$99K – 2626
2020
Q4 		$99K Buy
+28,054
New +$98.2K ﹤0.01% 1634
2020
Q2 		– Sell
-11,700
Closed -$11K – 1505
2020
Q1 		$11K Sell
11,700
-33,192
-74% -$89.8K ﹤0.01% 687
2019
Q4 		$124K Buy
+44,892
New +$72.6K 0.01% 1004

Other funds holding ABUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HRT Financial's ABUS Position: Q2 2022 in Review

HRT Financial sold out of Arbutus Biopharma (ABUS) in Q2 2022, closing a stake of 50,617 shares — an estimated $150K sold.

HRT Financial first reported a position in ABUS in Q4 2019 and held it in 5 quarters. The position peaked at $150K in Q1 2022. 113 funds tracked by Wall St. Rank hold ABUS as of Q2 2022.

  • HRT Financial reported no remaining Arbutus Biopharma position as of Q2 2022 after selling out during the quarter.
  • HRT Financial sold 50,617 Arbutus Biopharma shares in Q2 2022, an estimated $150K.
  • HRT Financial first reported a position in Arbutus Biopharma in Q4 2019 and held it in 5 quarters.
  • HRT Financial's Arbutus Biopharma position peaked at $150K in Q1 2022.
  • 113 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2022.

Based on HRT Financial's 13F filing for Q2 2022, filed 12 Aug 2022.